Phaseline

Companies › Alume Biosciences

Alume Biosciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Oncology, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bevonescein
Fluorescent imaging agent for nerve and tissue visualization
–Phase 2Surgery; Head and Neck Disorder–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06662097BevonesceinPhase 2SurgeryOtherJan 2026
NCT07631650BevonesceinPhase 2Head and Neck DisorderOncologyAug 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Haihe Biopharma Monte Rosa Therapeutics Angitia NanoEcho Syncromune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.